Key result
The β3-agonist mirabegron appears safe in patients at high cardiovascular risk but produces benefits on selected cardiovascular outcomes only at higher than standard doses.
Why the study?
Because β3-adrenoreceptors are expressed in human cardiac and vascular tissues, it is important to understand the beneficial or adverse cardiovascular effects of β3-agonists.
Do β-3 adrenergic receptor agonists improve cardiovascular outcomes and demonstrate safety in patients at high cardiovascular risk?
Do β-3 adrenergic receptor agonists improve cardiovascular outcomes and demonstrate safety in patients at high cardiovascular risk?
Answers are grounded in this paper and cite their sources.
β3-adrenoreceptor agonists like mirabegron appear safe in high cardiovascular risk patients but may require higher than standard doses for cardiovascular benefits, warranting testing of more potent agonists like vibegron.
INTRODUCTION: Few agonists of the third isotype of beta-adrenergic receptors, the β3-adrenoreceptor, are currently used clinically, and new agonists are under development for the treatment of overactive bladder disease. As the receptor is expressed in human cardiac and vascular tissues, it is important to understand their beneficial (or adverse) effect(s) on these targets. AREAS COVERED: We discuss the most recent results of clinical trials testing the benefit and safety of β3-adrenoreceptor activation on cardiovascular outcomes in light of current knowledge on the receptor biology, genetic polymorphisms, and agonist pharmacology. EXPERT OPINION: While evidence from small clinical trials is limited so far, the β3-agonist, mirabegron seems to be safe in patients at high cardiovascular risk but produces benefits on selected cardiovascular outcomes only at higher than standard doses. Activation of cardiovascular β3-adrenoreceptors deserves to be tested with more potent agonists, such as vibegron.
No takes yet. Share an insight, caveat, or question.
Balligand et al. (2023) conducted a review in cardiovascular diseases. β-3 adrenergic receptor agonists (e.g., mirabegron) was evaluated on cardiovascular outcomes. The β3-agonist mirabegron appears safe in patients at high cardiovascular risk but produces benefits on selected cardiovascular outcomes only at higher than standard doses.
Synapse has enriched 10 related papers. Consider them for comparative context: